3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Transitional Cell
16
Urinary Bladder Neoplasms
15
Carcinoma, Merkel Cell
10
Neoplasm Metastasis
8
Carcinoma, Renal Cell
8
Breast Neoplasms
8
Neoplasms
6
Triple Negative Breast Neoplasms
5
Melanoma
5
Ureteral Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Neuroendocrine Tumors
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Urothelial Cancer
1
Turcot syndrome
1
Thymoma
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
avelumab
×
1 year
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled